Ono Pharmaceutical (OTCMKTS:OPHLF) Hits New 52-Week High at $27.08

Shares of Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLFGet Rating) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $27.08 and last traded at $27.08, with a volume of 150 shares changing hands. The stock had previously closed at $24.62.

Separately, Zacks Investment Research raised shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating and set a $30.00 target price on the stock in a report on Tuesday, May 3rd.

The firm’s 50-day moving average is $25.73 and its 200-day moving average is $24.28. The company has a market capitalization of $13.92 billion, a PE ratio of 17.05 and a beta of 0.34.

About Ono Pharmaceutical (OTCMKTS:OPHLF)

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors.

Featured Articles

Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.